


PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification <sup>6</sup> : <b>C07K 14/54, 14/715, 16/24, 16/28, 16/42, A61K 38/17, 38/20, 39/395, G01N 33/68, 33/577</b></p>		<p>A1</p>	<p>(11) International Publication Number: <b>WO 97/48728</b> (43) International Publication Date: 24 December 1997 (24.12.97)</p>
<p>(21) International Application Number: <b>PCT/NL97/00345</b></p>		<p>(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, HU, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p>	
<p>(22) International Filing Date: <b>19 June 1997 (19.06.97)</b></p>			
<p>(30) Priority Data: <b>96201720.8 20 June 1996 (20.06.96) EP</b> (34) Countries for which the regional or international application was filed: <b>AT et al.</b></p>			
<p>(71) Applicant (for all designated States except US): <b>KOSTER, Henk, Wilhelmus [NL/MC]; 1607 Parc Saint Roman, MC-98000 Monte Carlo (MC).</b></p>		<p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i></p>	
<p>(72) Inventors: and</p>			
<p>(75) Inventors/Applicants (for US only): <b>VAN LEENGOED, Leonardus, Andrianus, Maria, Govardus [NL/NL]; Oostrandpark 6, NL-8212 AN Lelystad (NL). HOEBE, Kasper, Hubertus, Nicolaas [NL/NL]; Tolsteegplantsoen 46, NL-3523 AN Utrecht (NL). HOEBE, Kasper, Hubertus, Nicolaas [NL/NL]; Karveel 10-04, NL-8231 AP Lelystad (NL).</b></p>			
<p>(74) Agent: <b>SMULDERS, Th., A., H., J., Vereenigde Octrooibureaux, Nieuwe Parklaan 97, NL-2587 BN The Hague (NL).</b></p>			

(54) Title: **IL-6 AND IL-6-RECEPTOR DERIVED PEPTIDES HAVING IL-6 ANTAGONISTIC OR AGONISTIC ACTIVITY**

(57) Abstract

The invention relates to IL-6 and IL-6-receptor derived peptides having IL-6 agonistic or antagonistic activity. The peptides are at least 5 amino acids long and are selected from one of the following amino acid sequences: RYILDGISALRK, STKVLIQFLQKKAKNL, ILRSFKEFLQSSLRALRQMQLSFRKSPLSNVVC, PRSTPSLTTKAVLLVRKFQNS, MCVASSVGSKFSKTQTFQGC, PEKPKNLSCIVNEGKKMRCEWDGGR, NFLKSEWATHKFADCKAKRDTPTS, WVEAENALGKVTSRH, EWGPRSTP-SLTTKAVLLVRKFQNSPAED or PVYKVKPNNPHNLSVIN. Selected peptides and combinations of selected peptides can be used in the treatment, prevention, detection, or diagnosis of IL-6 related disease and can be used to clear blood or bloodproducts of IL-6 or IL-6 receptor molecules.

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NP	Nepal	VN	Viet Nam
CG	Congo	KF	Kosovo	NR	Northern Cyprus		

HR	Croatia	KK	Republic of Korea	MP	Montenegro
IS	Iraq	KZ	Kazakhstan	RO	Romania
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation
DE	Germany	LI	Liechtenstein	SD	Sudan
DK	Denmark	LK	Sri Lanka	SE	Sweden
EE	Estonia	LR	Liberia	SG	Singapore

## IL-6 AND IL-6-RECEPTOR DERIVED PEPTIDES HAVING IL-6 ANTAGONISTIC OR AGONISTIC ACTIVITY

The invention relates to the field of cytokines. Cytokines are substances that are produced by cells of the immune system and are involved in regulation of humoral and cellular immune reactions and inflammatory responses. Many cytokines are known, and all exert influence on various reactions in the body in a complicated fashion. To illustrate their interdependency and the intricate web of relationships that exist between cytokines, one often speaks about the "cytokine network".

10 Interleukine 6 (IL-6) is a cytokine which has many effects upon mammalian cells. It exerts these effects through binding to a specific cell surface receptor, that consists of a specific  $\alpha$ -subunit of with a molecular weight of approximately 80 kD and a common  $\beta$ -subunit of approximately 130 kD, also named gp130. The gp130  $\beta$  chain is also involved in signal transduction of interleukin-11 (IL-11), leukemia inhibitory factor (LIF), oncostatin M (OM), ciliairy neurotrophic factor (CNTF), and cardiotrophin-1 (CT-1) (P.B. Sehgal, Ling Wang, Ravi Rayanade et al., pp 1-14; volume 762, Annals of the New York Academy of Sciences; 1995).

15 IL-6 is an extremely pleiotropic cytokine, and its activities include: induction of Ig production by B cells, stimulation of B and T cell growth, differentiation of T cells and macrophages, induction of acute phase protein production by hepatocytes, multilineage hematopoesis, osteoclast formation, maturation of megakaryocytes, and platelet production. IL-6 also effects the central nervous system: IL-6 is an endogenous 20 pyrogen and can induce ACTH production by the pituitary

25 transmembrane receptor that is present on all target

cells. Specific steps in the IL-6 signaling cascade are the binding to the low affinity  $\alpha$ -chain (CD126). The complex of IL-6 and  $\alpha$ -chain binds with the high affinity signal transducing  $\beta$ -chain (GP130, CD130).

5 In healthy individuals no or only very low levels of IL-6 (<10 pg/ml) are detectable in the circulation. IL-6 levels are increased in various diseases, and it is postulated that these increased levels play a causative role in the pathogenesis of these diseases. Examples of  
10 diseases where increased levels of IL-6 are found are multiple myeloma, AIDS lymphoma, polyclonal B cell activation as observed in AIDS, rheumatoid arthritis, cardiac myxoma and Castleman's disease, mesangial proliferative glomerulonephritis, psoriasis, cancer-  
15 associated cachexia, postmenopausal osteoporosis, sepsis, multiple system organ failure, alcohol cirrhosis, and diseases of the central nervous system like Alzheimer, among others. Evidence for the causative role of IL-6 in the pathogenesis of some of the above mentioned diseases  
20 has come from phase I/II clinical trials with IL-6 neutralizing monoclonal antibodies. Treatment with anti-IL-6 monoclonal antibodies reversed fever, acute phase proteins, night sweats, bone destruction, and cachexia. Treatment of a patient with Castleman disease with anti-  
25 IL-6 monoclonal antibodies reduced acute phase protein levels, fever, anemia, thrombocytosis, and hypergammaglobulinemia. Improvement of patients was also observed in patients with rheumatoid arthritis. Apparently, reduction of IL-6 activity in these patients resulted in  
30 improvement of the clinical signs of their disease.

This approach for treating disease by antagonizing IL-6 activity makes use of monoclonal antibodies directed to IL-6. However, monoclonal antibodies are usually not

present in the body of the patient, since this is foreign to the body of the patient. This

immunereaction to the monoclonal antibodies used in the treatment is, first of all, counterproductive to the therapeutic treatment itself. The monoclonal antibodies used will be rendered ineffective by the reaction with 5 the antibodies produced by the immune system. Secondly, repeated administration of non-human monoclonal antibodies may elicit such **severe** immune reactions that they will be detrimental to the patient. Methods for producing less antigenic antibody fragments and methods 10 for humanizing antibodies have been proposed, but, if feasible at all, these methods are not very economical and will their own give rise to problems regarding to half-life and bio-availability. Consequently, using anti-IL-6 monoclonal antibodies in the treatment of IL-6 15 related disease is considered not to be feasible.

Inhibitors or antagonists based upon mutagenesis of IL-6 have also been proposed, such as IL-6.Q160E /T163P (Brakenhoff, J., de Hon, F., Fontaine, V., et al; J.Biol.Chem.; 269:86-93 (1994)), and IL-6.Q159E/T162P 20 (Ehlers, M., de Hon, D., Klaasse Bos, H, et al., J. Biol. Chem.; 270:8158-8163 (1995)). It has been shown with these mutant proteins that receptor binding of IL-6 and signal transduction of IL-6 can be separated in vitro. However, such mutant proteins are also foreign to the 25 body of the patient to be treated and will also elicit an unwanted and unfavourable immune response that generally is detrimental to the treatment. Furthermore, such mutant proteins may only be partly effective, in that, although they may effectively block or inhibit specific IL-6 30 activities, at the same time they may exert other effects on the cytokine network with additional, still remaining, reactive sites present on these proteins. Therapeutic treatment with such reagents would then elicit other, yet 35 undefined, side effects.

Inhibiting IL-6 in vivo, act as carrier and increase the

half-life time and result in an increase of IL-6 activity in vivo. Moreover, these mutant IL-6 and IL-6 receptor antagonists have a low affinity to their target molecules and will likely act as an immunogen. In addition, 5 antibodies raised to IL-6 stabilize IL-6 and result in an increased IL-6 production. Accumulation of circulating IL-6 as stable IL-6-anti-IL-6 complexes as a result of treatment with these antibodies to IL-6, will occur as no renal filtration can be expected. Repeated use of 10 nonhumanized IL-6 antibodies to human patients will most likely induce antibody production to these antibodies, and result in formation of immune-complexes (Heremans, H., Dillen, C., et al J. Immunol. 22, 2395-2401).

The present invention provides a solution to the 15 above illustrated problems without hampering the possibility of therapeutic treatment of IL-6 related disease. The above methods to inhibit IL-6 activity by antibodies or mutants, differ greatly from the invention as described here: peptides that antagonize or agonize 20 IL-6 at the binding site to the receptor in three ways: at the IL-6 part, at the  $\alpha$ -receptor part, and at the gp130-receptor part. These antagonists and agonists and combinations of these antagonists and/or agonists as multimeric peptides or as single peptides with defined 25 pharmacokinetic characteristics gives a powerful tool to manage IL-6 bioactivity. With the solution provided by the present invention, immune responses to the treatment do not occur. Further, the occurrence of unpredictable side effects is greatly minimized.

30 The invention provides synthetic peptides that interact with the receptor site of IL-6 or with IL-6 receptors ( $\alpha$  and  $\beta$ ) present at target cells.

The invention further provides synthetic peptides

and a mixture of these peptides is particularly valuable as the pharmacological properties of the

peptides can be adjusted to obtain a maximal desired effect. Moreover, half-life time can be prolonged by inserting unnatural amino-acids into the synthetic peptides. The antagonizing or agonizing activity of the peptides is increased by producing di- or multi-meric peptides directed to one or more receptor sites. Such di- or multimeric peptides can for instance be made by linking the peptides via one or more amino-acids such as lysine (Tam, PNAS 1988, 85: 5409-5413). The distribution of the peptides into target organs can be optimized by adjusting the hydrophilic or lipophylic nature of peptides or by binding of these peptides onto peptides that interact with specific organ markers. Finally, the peptides provided can be bound onto the solid phase of membranes or filters that are connected into an extracorporeal blood circulation circuit of the patient. A more efficient clearance of IL-6 and/or soluble IL-6 receptors can in that way be achieved.

Such synthetic peptides can be derived from (A) IL-6, or derived from (B) the receptor  $\alpha$ -chain of IL-6 (IL-6Ra, CD126), or from (C) the receptor  $\beta$ -chain of IL-6 (IL-6R $\beta$ , GP130, CD130) and exhibit antagonistic and agonistic activity against the various components and steps of the IL-6 signaling cascade. The peptides were found by testing sets of overlapping amino acid sequences from the published human IL6 (Hirano, T., Yasukawa, K., Harada, H., et al.; Nature 324, 73-76 (1986); Yasukawa, R., Hirano, T., Watanabe Y., et al.; EMBO J. 6:2939-2945 (1987), IL-6Ra (Yamasaki, K., Taga, T., Hirata, Y., et al.; Science 241:825-828 (1988)) and IL-6R $\beta$  (Hibi, M., Murakami, M., Saito, M.; Cell 63:1149-1157 (1990)). These overlapping peptides, each twelve amino acids long, were tested in an assay for antagonistic or agonistic IL-6

signaling cascade as measured in an IL-6 assay. The

peptides of the present invention are too small to generate immune responses. Further, they are too short to contain additional reactive sites, so that the antagonistic and, in addition, the agonistic peptides can 5 advantageously be used to treat patients to counteract and adjust elevated IL-6 levels. The amino acids in all antagonistic or agonistic peptides described below are identified by the one letter code, in which the N-terminal (head) amino acid is listed first (on the left) 10 and the C-terminal (tail) amino acid is listed last (on the right).

A. The antagonistic peptides derived from IL-6 preferably comprise at least 5 consecutive amino acids selected from the following 3 regions that were 15 identified as RYILDGISALRK, STKVLIQFLQKKAKNL, and I-LRSFKEFLQSSLRALRQM.

B. The antagonistic peptides derived from the receptor  $\alpha$ -chain of IL-6 preferably comprise at least 5 consecutive amino acids selected from the following 3 20 regions that were identified as QLSCFRKSPLSNVVC, PRSTPSLTTKAVLLVRKFQNS, and MCVASSVGSKFSKTQTFQGC. The agonistic peptides derived from the receptor  $\alpha$ -chain of IL-6 preferably comprise at least 5 consecutive amino acids selected from the following region that was 25 identified as EWGPRSTPSLTTKAVLLVRKFQNSPAED.

C. The antagonistic peptides derived from the receptor  $\beta$ -chain of IL-6 preferably comprise at least 5 consecutive amino acids selected from the following 4 regions that were identified as PEKPKNLSCIVNEGKKMRCE- 30 WDGGR, NFLKSEWATHKFADCKAKRDTPTS, WVEAENALGKVTSDH, and PVYKVKPNPPHNLSVIN.

Relatively short peptides (as short as a string of 5 amino acids) that are selected from any of the above

peptides and that are substantially similar to the peptides of the present invention, may be selected by including at least 2 amino acids in common with the peptides from groups A,

B or C, are also peptides of the present invention. The peptides according to the invention can vary in length. Also, the peptides comprising a string of at least 5 amino acids which are in common with the peptides from 5 groups A, B, and C can be modified by replacing one or a few amino acids in said string by other amino acids. Such amino acids can be selected from any of the naturally occurring amino acids, but also amino acids that normally do not occur in nature can be used as replacement amino 10 acid. The choice of the replacing amino acid can for example be guided by comparing IL-6 or IL-6 receptor sequences from other species than humans or by selecting amino acids that lead not to extreme functional or conformational changes of the selected peptide, but also 15 other selection methods can be used. More in particular, the present invention relates in a first aspect to a peptide containing at least 5 amino acids and at most 30 amino acids that exhibits antagonistic activity directed 20 against IL-6 and/or against the  $\alpha$ -chain of the IL-6 receptor and/or against the  $\beta$ -chain of the IL-6 receptor.

Also, the present invention relates in another aspect to a peptide containing at least 5 amino acids and at most 30 amino acids that can exhibit antagonistic or agonistic IL-6 activity, depending on the concentration 25 in which it is used. An example of such peptides are peptides selected with as basis with the amino acid sequence EWGPRSTPSLTTKAVLLVRKFQNSPAED as found in the  $\alpha$ -chain of the IL-6 receptor. Surprisingly, peptides selected on the basis of the aforementioned sequence 30 expressed antagonistic IL-6 activity at high concentrations whereas at low concentrations a marked agonistic activity was found. Agonistic activity was observed in the in vitro bioassay in a concentration

of 100 nM. Agonistic activity is lost in the bioassay. The agonistic peptides can be used in vivo in concentrations

that are relatively equivalent but not necessarily the same as when used in vitro.

Furthermore, the invention provides combinations of peptides, either provided as a simple mixture of several, 5 possibly modified, peptides selected from groups A, B or C, or, provided as, possibly modified, peptides selected from groups A, B, or C that are linked, with direct chemical bonds or using spacer molecules, head to tail, or head to head, or tail to tail, or via side chains of 10 the amino acids present in the selected peptides.

Examples of such combinations of peptides are for example using the peptides SLTTKAV and ILRSFKEFLQSS, or WVEAENALGKVTSRH and RYILD, or KAVLLVRK and KAVLLVRK, but many other combinations of two or more peptides can be 15 selected from the peptides listed in groups A, B or C. Such combinations of peptides, be it simple mixtures or bound peptides, can advantageously be used to counteract the events occurring in the IL-6 signaling cascade, such as disrupting the binding of IL-6 to the  $\alpha$ -chain by 20 simultaneous competing at both the IL-6 and the  $\alpha$ -chain binding site, or simultaneous competing at the binding sites of the IL-6/ $\alpha$ -chain complex and the  $\beta$ -chain.

The peptides of the invention can suitably be used in a medicinal or pharmaceutical preparation for 25 therapeutic or prophylactic purposes. Further, they can be used in protocols to remove circulating IL-6 from the blood of diseased patients via dialysis methods in which the peptides are bound to a solid phase. Passing blood or blood filtrates along the thus bound peptides will result 30 in clearance of IL-6 that will bind to the peptide at the solid phase. Also the peptides according to the invention may be added to blood or blood filtrates and (ir)- reversibly bind to IL-6 or IL-6 receptor molecules and

immunoassays to measure IL-6 levels.

IL-6 agonistic peptides can completely or partially replace IL-6 that is added to cell-cultures, for example IL-6 is used to grow or culture IL-6 dependant cells, like B-cell hybridomas to which IL-6 as growth factor is 5 often added, but also cell-cultures in general will benefit from the addition of agonistic IL-6 peptides. The IL-6 agonistic peptides administered to humans or animals can be used to enhance the immune response of an host exposed to a specific immunogenic substance. The IL-6 10 agonistic peptides can be administered to humans or animals to increase the responsiveness of the immune system of the host. A specific use is in pharmaceutical preparations for topical or intramammary application. When these agonistic peptides are combined with IL-6 15 antagonists as described, excess of IL-6 can be inhibited without loss of basal IL-6 signal transduction.

Antibodies specifically directed against the peptides, and their corresponding anti-idiotypic antibodies, are part of the invention. Such antibodies can for 20 example be administered to patients treated earlier with the peptides, to counteract the effect of the peptides on the patient. Such antibodies can be used in the above described dialysis protocols and diagnostic tests.

Synthesis of the peptides may be accomplished 25 according to the available methods in the art. The synthesis of the exemplified peptides was done according to Valerio et al. (Int. J. Peptide Res., 42:1-9 (1993) and/or Valerio et al. (Int. J. Peptide Res., 44:148-165 (1994)). Methods for large scale production of synthetic 30 peptides and the purification thereof are well known in the art. The invention is illustrated in the following experimental part.

## Experimental part

1. Peptide synthesis.

The peptides of the examples which were intended for 5 identifying active centers in the IL-6 and IL-6 receptor molecules were synthesized using a method according to Valerio et al. (Int. J. Peptide Res., 42:1-9 (1993) and/or Valerio et al. (Int. J. Peptide Res., 44:148-165 (1994)). Multimeric peptides (four branched) were 10 synthetized by the solid-phase method and using of a dispersed system with branching oligolysines as a scaffolding for incorporation of the synthetized antagonistic peptides (Tam, J.P.; Proc. Natl. Acad. Sci. USA, 85:5409-5413 (1988)).

15

2. Proliferation assay to determine antagonistic IL-6 activity.

A set of overlapping peptides, each twelve amino acids long (each consecutive peptide shifts one amino 20 acid, so consecutive peptides have 11 amino acids in common), derived from human IL-6 sequence (Hirano, T., Yasukawa, K., Harada, H., et al.; Nature 324, 73-76 (1986); Yasukawa, R., Hirano, T., Watanabe Y., et al.; EMBO J. 6:2939-2945 (1987), were incubated with cells 25 (B9) at 37°C. After one hour, recombinant human IL-6 (CLB, Amsterdam, The Netherlands) was added at 3 different concentrations (2.5 U/ml, 5 U/ml and 10 U/ml).

A set of overlapping peptides, each twelve amino acids long (each consecutive peptide shifts one amino 30 acid, so consecutive peptides have 11 amino acids in common), derived from human IL6Ra (Yamasaki, K., Taga, T., Hirata, Y., et al.; Science 241:825-828 (1988)) or gp130 (Hibi, M., Murakami, M., Saito, M.; Cell 63:1149-

supplemented with IL-6 for one hour at 37°C. Then the residual IL-6 activity was determined in a biological

assay by measuring the IL-6 dependant proliferative growth of B9 mouse hybridoma cells (Helle, M., Boeije, L., Aarden, L.A.; Eur. J. Immunol. 18:1535-1540 (1988)). Briefly, B9 mouse hybridoma cells were collected during their logarithmic growth phase in IL-6 free media and suspended at a concentration of  $1 \times 10^5$  cells/ml in DMEM+HT medium containing 5% FCS. Fifty  $\mu$ l of each IL-6 dilution was combined with each of the synthetized peptides representing IL-6 sequences and incubated for 1 hour at 37°C. This mixture was added in duplicate to 50  $\mu$ l of the B9 cell suspension in flat-bottomed 96-well tissue culture plates (Greiner) and incubated at 37°C and 5% CO<sub>2</sub> for 72 h. IL-6 activity was assessed by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma). After addition of 25  $\mu$ l of MTT (5mg/ml dissolved in PBS) to each well and further incubation at 37°C for 4 h, 100  $\mu$ l of lysis buffer (20% w/v SDS in 50 % dimethyl formamide) was added. Thereafter, incubation was continued over night at 37°C and the next morning absorbance was read at 578 nm.

To determine the agonistic or antagonistic activity to IL-6 of the peptides synthetized from the sequences of the IL-6 receptor  $\alpha$  or  $\beta$ , various concentrations of each of these peptides was combined with 50  $\mu$ l of the B9 cell suspension ( $1 \times 10^5$  cells/ml in DMEM+HT medium containing 5% FCS). This suspension was incubated for 1 hour at 37°C, and combined with each of the dilutions of IL-6 into flat-bottomed 96-well tissue culture plates (Greiner). Plates were incubated at 37°C for 72 h. IL-6 activity was assessed as described above.

Samples without synthetized peptides or with a sham peptide but with IL-6 were used as positive control, whereas samples that contained neither IL-6 nor

absorbance positive control both corrected for negative control absorbance.

### 3. Toxicity testing of peptides

5 Three separate tests were performed to determine whether the synthesized peptides exert toxic effect in vitro upon erythrocytes (A), or polymorphonuclear cells (B), or hepatocytes (C).

A. Sheep red blood cells (SRBC) were washed five times 10 in PBS. A 1% (v/v) suspension of erythrocytes was prepared in veronal-buffered saline that contained gelatin (GVS: 0.032% gelatin in 3.9 mM barbitone sodium, 1 mM MgSO<sub>4</sub>, 0.38 mM CaCl<sub>2</sub>, and 145.6 mM NaCl). Twofold dilutions of the synthesized peptides (50 µl) were made 15 in U-shaped microtiter plates (Greiner Labortechnik) and 50 µl of the SRBC suspension were added to each well. Plates were sealed, mixed and incubated for 2 hours at 37°C. Thereafter, plates were examined for hemolysis. None of the synthesized peptides showed hemolysis.

B. Porcine polymorphonuclear cells (PMN) were isolated 20 from pig blood (Cruijssen, T.L.M., Van Leengoed, L.A.M.G. et al.; Infect. Immun. 60:4867-4871 (1992)). Twofold dilutions of the synthesized peptides (50 µl) were made in flat-bottomed microtiter plates (Greiner Labortechnik) 25 and 50 µl of the PMN suspension (2\*10<sup>6</sup> cells/ml) were added to each well. Plates were sealed, gently mixed and incubated for 6 hours at 37° and 5% CO<sub>2</sub>. Thereafter, plates were examined for cytotoxicity by nigrosine dye exclusion. None of the synthesized peptides was toxic for 30 PMN.

C. Porcine hepatocytes were isolated from liver of pigs based on Seglens' method (Seglen, P.O.; Methods Cell Biol 13:29-83 (1976)) and adapted according to Monshouwer M.

1.5\*10<sup>6</sup> cells/ml from this suspension 1.5 ml was put into each well of 12-well tissue culture plates (Costar) and

incubated for 12 h at 37°C. Adherent hepatocytes were examined for their viability and nonadherent hepatocytes were discarded. Each synthetized peptide was mixed with Williams' medium E (at dilutions of 1:50 and 1:100) and 5 added to wells with adherent hepatocytes. After another 24 h incubation at 37°C viability was assessed by using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma). After addition of 1.5 µg of MTT (1-  
10 mg/ml dissolved in Williams' medium E) to each well and further incubation at 37°C for 30 min, 1 ml of lysis buffer (0.8 M HCl in isopropanol) was added. Thereafter, plates were mixed for 10 min and absorbance was read at 560 nm. None of the synthetized peptides proved to affect the viability of the hepatocytes.

15

4. Effect of IL-6 antagonistic peptides upon IL-6 induced acute phase reaction and downregulation of hepatic biotransformation activities.

Porcine hepatocytes were isolated from liver of pigs 20 based on Seglens' method (Seglen, P.O.; Methods Cell Biol 13:29-83 (1976)) and adapted according to Monshouwer M., et al. (Toxicol. Applied Pharmacol. in press). Hepatocytes were suspended in Williams' medium E to a concentration of 10<sup>6</sup> cells/ml. From this suspension 1 ml was put into 25 each well of 12-well tissue culture plates (Costar) and incubated for 12 h at 37°C. Adherent hepatocytes were examined for their viability and nonadherent hepatocytes were discarded. Each synthetized peptide was mixed (at dilutions of 1:50 and 1:100) with Williams' medium E 30 containing IL-6 (1000 U/ml) and added to wells with adherent hepatocytes. Also a negative (containing no IL-6 and without synthetized peptides in the medium) and positive control (containing 1000 U/ml IL-6 in the

medium) were prepared. Viability of the adherent monolayers of hepatocytes was determined.

CYP450 enzym assay. CYP450 dependent enzym activity, using testosterone (250 $\mu$ M) as substrate, was determined as previously described by Van 't Klooster et al. (Bioch. Pharmacol. 46;1781-1790 (1993)). Briefly, testosterone was 5 mixed with Williams' medium E without fetal calf serum and added to the wells with hepatocytes. After 30 min incubation at 37°C and 5%CO<sub>2</sub>, hydroxylated testosterone metabolites in the medium were quantified by HPLC.

HPLC analysis. Aliquots of 1 ml of medium was mixed 10 with 100  $\mu$ l of a solution of 11 $\beta$ -testosteron (12,5  $\mu$ g/ml) in methanol as internal standard and extracted with 5 ml dichlormethane. The organic phase was transferred to clean tubes and evaporated to dryness at roomtemperature under a stream of nitrogen. The residues were dissolved 15 in 130  $\mu$ l 50% methanol and 20  $\mu$ l of these solutions were injected for HPLC analysis. The stationary phase consisted of a C18 glasscolumn (20 cm, 3 $\mu$ m particle size, Chrompack, Middelburg, the Netherlands). The mobile phase consisted of buffer A (12% methanol, 75% milli Q water) 20 and buffer B (64% methanol, 6% acetonitril, 30% milli Q water). With these buffers an elution gradient was generated; 10-58% B from 0-45 minutes; 58-59% from 45-50 minutes; 59-10% from 50-53 minutes, with a flow rate of 0,8 ml/min. Metabolites were detected 25 spectrophotometrically at 254 nm. Inhibition of IL-6 dependant downregulation of cytochrome P450 was determined by comparing the relative concentration of hydroxylated testosterone metabolites in medium from adherent hepatocytes incubated with synthetized peptides 30 and IL-6, and the relative concentration of hydroxylated testosterone metabolites in medium from positive and negative control hepatocyte monolayers.

The antagonistic activity of the peptides on the IL-6 receptor were analysed for antagonistic IL-6 activity.

For hIL-6 peptides, 3 regions were identified which inhibited IL-6 activity in an IL-6 assay (fig. 2).

Peptide 31, 119-123 and 167-174 represent the identified regions (RYILDGISALRK, resp. STKVLIQFLQKKAKNL, resp.

5 ILRSFKEFLQSSLRALRQM).

For hIL6Ra, also 3 regions were identified which inhibited IL-6 activity in an IL-6 assay (fig. 3). Peptide 6-9, 24-33 and 80-89 represent the identified regions (QLSCFRKSPLSNVVC, resp. PRSTPSLTTKAVLLVRKFQNS, resp.

10 MCVASSVGSKFSKTQTFQGC).

For hgpl30 peptides, 4 regions were identified which inhibited IL-6 activity in an IL-6 assay (fig. 4).

Peptide 2-15, 33-46, 73-76 and 92-97 represent the identified regions

15 (PEKPKNLSCIVNEGKKMRCEWDGGR, resp. NFTLKSE-WATHKFADCKAKRDTPTS, resp. WVEAENALGKVTSDH, resp. PVYKVKPNPPHNLHSVIN).

The identified peptides with anti-IL-6 activity were not lytic for erythrocytes and not toxic for polymorpho-20 nuclear cells and not toxic for primary hepatocyte culture cells.

Peptides derived from hIL6Ra (the  $\alpha$ -chain of the IL-6 receptor) were analysed for agonistic IL-6 activity and 1 region was identified which stimulated proliferation of 25 B9 cells without IL-6 added to the medium and enhanced IL-6 activity in the B9 bio-assay (fig. 5). Peptide 21-37 represent the region EWGPRSTPSLTTKAVLLVRKFQNSPAED of the IL-6Ra sequence

Agonistic activity was observed in a concentration 30 range from 7.5 to 120  $\mu$ g/ml peptide. These peptides induced proliferative growth of the IL-6 dependant cell line B9, and when combined with IL-6 enhanced proliferation of the B9 cell line was examined, and thus

The identified peptides with agonistic IL-6 activity were not lytic for erythrocytes and not toxic for polymorphonuclear cells and not toxic for primary hepatocyte culture cells.

5       Synthetized peptides from the regions PVYKVKPNNPP-HNLSVIN, WVEAENALGKVTSDH, and MCVASSVGSKFSKTQTFQGC inhibit IL-6 regulated downregulation of cytochrome P-450 of hepatocytes.

CLAIMS

- 1 A peptide containing 5-30 amino acids which peptide exhibits antagonistic activity directed against IL-6.
- 2 A peptide containing 5-30 amino acids which peptide exhibits antagonistic activity directed against the  $\alpha$  and/or  $\beta$ -chain of the IL-6 receptor.
- 3 A peptide containing 5-30 amino acids which peptide exhibits antagonistic and/or agonistic IL-6 activity.
- 4 A peptide according to claim 1, 2 or 3 containing 5-20 amino acids.
- 10 5 A peptide according to claim 4 containing 5-12 amino acids.
- 6 A peptide according to claim 1, 2, 3, 4 or 5 having at least one string of 5 consecutive amino acids long in common with one of the following amino acid sequences:
- 15 RYILDGISALRK, STKVLIQFLQKKAKNL, ILRSFKEFLQSSLRALRQM, QLSCFRKSPLSNVVC, PRSTPSLTTKAVLLVRKFQNS, MCVASSVGSKFSKTQTFQGC, PEKPKNLSCIVNEGKKMRCEWDGGR, NFLTLS- EWATHKFADCKAKRDTPTS, WVEAENALGKVTSDH, or PVYKVKPNPPHNLSVIN.
- 20 7 A peptide according to claim 3, 4 or 5 having at least one string of 5 consecutive amino acids long in common with the following amino acid sequence: EWGPRSTPSLTTKAVLLVRKFQNSPAED
- 8 A peptide composition, wherein at least two peptides according to any of claims 1-7 are chemically linked directly or via spacer molecules.
- 25 9 A peptide composition according to claim 8 wherein at least two peptides are linked with lysine.
- 10 A peptide composition according to claim 8 wherein

- 11 A mixture comprising peptides and/or peptide compositions according to any of claims 1-10.
- 12 Antibody specifically directed against a peptide or a peptide composition according to any of claims 1-10.
- 5 13 Anti-idiotypic antibody raised against an antibody according to claim 12.
- 14 A pharmaceutical preparation comprising a peptide or a peptide composition or an antibody according to any of the above claims together with at least one suitable 10 excipient for administration.
- 15 Use of a pharmaceutical preparation according to claim 14 in the treatment or prevention of an IL-6 related disease.
- 16 Use of a peptide, peptide composition or antibody 15 according to anyone of claims 1-12 to clear extra-corporeal blood or blood products from IL-6 or IL-6 receptor molecules.
- 17 A diagnostic assay comprising a peptide or a peptide composition or an antibody according to anyone of claims 20 1-12.
- 18 Use of a diagnostic assay according to claim 17 to detect or diagnose IL-6 related disease in man or animals.
- 19 Use of a peptide according to claim 7 to exert 25 agonistic IL-6 activity at concentrations that are relatively equivalent to 7.5 to 120 µg/ml.
- 20 Use of a peptide according to claim 19 in cell-culture.
- 21 A pharmaceutical preparation comprising a peptide 30 according to claim 7 or 19 together with at least one suitable excipient for administration.
- 22 Use of a pharmaceutical preparation according to claim 21 for topical or intra-mammary application.

Fig. 1. Amino acid sequences and sources of selected peptides.

Peptides were selected from published sequences of IL-6 (A) and IL-6  $\alpha$ - (B) and  $\beta$ -receptor (C).

A) human IL6 (Hirano, T., Yasukawa, K., Harada, H., et al.; Nature 324, 73-76 (1986); Yasukawa, R., Hirano, T., Watanabe Y., et al.; EMBO J. 6:2939-2945 (1987))

Amino acid sequence:

APPVPPGEDSKDVAAPHRQPLTSSERIDKQIRYILDGISALRKETCNKSNMCESSKEALAENNLLNPKMAEKDGCFQSGFNEETCLVKIITGLLEFEVYLEYLQNRFESSEEQ-ARAVQMSTKVLILQFLQKKAKNLDAITTPDPTTNASLLTKLQAQNQWLQDMTTIILILRSFKEFLQSSLRALRQM

B) the receptor  $\alpha$ -chain of IL-6 (IL-6Ra, CD126), (Yamasaki, K., Taga, T., Hirata, Y., et al.; Science 241:825-828 (1988))

Amino acid sequence:

PPEEPQLSCFRKSPLSNVVCEWGPRSTPSLTTKAVLLVRKFQNSPAEDFQEPCQY-SQESOKFSCOLAVPEGDSSFYIVSMCVASSVGSKFSKTQTFQGCGILQPDPPANITV

C) the receptor  $\beta$ -chain of IL-6 (IL-6R $\beta$ , GP130, CD130) (Hibi, M., Murakami, M., Saito, M.; Cell 63:1149-1157 (1990))

Amino acid sequence:

PPEKPKNLSCIVNEGKKMRCEWDGGRETHLETNFTLKSEWATHKFADCKAKRDT-PTSCTVDYSTVYFVNIEVVWVEAENALGKVTSVDHINFDPVYKVKPNNPHNLSVIN

IL-6 peptides  
dilution 1:20




Fig 2: Screening of synthesized peptides, representing IL-6, in the B9 bio-assay

IL6Ra peptides  
dilution 1:20




Fig 3: Screening of synthesized peptides, representing IL-6Ra, in the B9 bio-assay

gp130 receptor peptides  
dilution 1:20




Fig 4: Screening of synthesized peptides, representing gp130, in the B9 bioassay

hLL6Ra peptides  
dilution 1:50




Fig 5: Screening synthetic peptides showing a region with agonistic activity (dilution 1:50)

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/NL 97/00345

A. CLASSIFICATION OF SUBJECT MATTER					
IPC 6	C07K14/54	C07K14/715	C07K16/24	C07K16/28	C07K16/42

A61K38/17      A61K38/20      A61K39/395      G01N33/68      G01N33/577

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07K A61K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	<p>DATABASE WPI Week 9607 Derwent Publications Ltd., London, GB; AN 96-065477 XP002027134 &amp; JP 07 324 098 A (DAICEL CHEM. IND. LTD. ET AL.) , 12 December 1995 see abstract</p> <p>---</p>	1,3,6, 14-16
X	<p>DATABASE WPI Week 9607 Derwent Publications Ltd., London, GB; AN 96-065476 XP002027135 &amp; JP 07 324 097 A (DAICEL CHEM. IND. LTD. ET AL.) , 12 December 1995 see abstract</p> <p>---</p> <p>-/-</p>	1-6, 14-16

Further documents are listed in the continuation of box C

Patent family members are listed in annex.

\* Special categories of cited documents .

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier document but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date (as filed)

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

\*\* The following documents are cited in the continuation of box C

\*\*\* The following documents are cited in the continuation of box C

26 October 1997

Name and mailing address of the ISA  
European Patent Office, P.B. 5818 Patentbuurt 2  
NL - 2280 HV Rijswijk  
Tel (+31-70) 340-2040, Telex 11 651 epx n  
Fax (+31-70) 340-3016

Authorized officer

Hoorn

## INTERNATIONAL SEARCH REPORT

International Appl. No.  
PCT/NL 97/00345

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Description of document, with indication, where appropriate, of the relevant passages	Relevant to claim No
X	DATABASE WPI Week 9035 Derwent Publications Ltd., London, GB; AN 90-266224 XP002027136 & JP 02 188 600 A (CHUGAI PHARMACEUTICAL KK) , 24 July 1990 see abstract ---	1,3,6, 14-18
X	WO 95 04075 A (MEDVET SCIENCE PTY. LTD.) 9 February 1995 see examples 15,16 see seq. id. nos 17,36,37 see table 2 ---	1-7, 14-16,21
X	EP 0 426 857 A (KURARAY CO. LTD.) 15 May 1991 see claim 7 ---	2,3,6,7, 16
X	US 5 210 075 A (SCHOLZ ET AL.) 11 May 1993 see examples ---	1-5,12, 14-16
X	C. MORTON ET AL.: "Solution structure of synthetic peptides corresponding to the C-terminal helix of interleukin-6." EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 219, no. 1-2, 15 January 1994, BERLIN, GERMANY, pages 94-107, XP000645297 see page 98, left-hand column, line 50 - line 61 see page 105, right-hand column, line 20 - page 106, left-hand column, line 4 ---	1,3,4,6, 7
A	M. KALAI ET AL.: "Participation of two Ser-Ser-Phe-Tyr repeats in interleukin-6 (IL-6) binding sites of the human IL-6 receptor." EUROPEAN JOURNAL OF BIOCHEMISTRY, vol. 238, no. 3, June 1996, BERLIN, GERMANY, pages 714-723, XP000645294 see table 1 -----	12

# INTERNATIONAL SEARCH REPORT

International Application No.  
PCT/NL 97/00345

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

- 1  Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
see FURTHER INFORMATION sheet PCT/ISA/210
- 2  Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
- 3  Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

- 1  As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
- 2  As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
- 3  As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
- 4  No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

### Remark on Protest

The additional search fees were accompanied by the applicant's protest

No protest accompanied the payment of additional search fees

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/NL 97/00345

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
WO 9504075 A	09-02-95	AU 7341494 A		28-02-95
		CA 2168261 A		09-02-95
		EP 0715633 A		12-06-96
		JP 9501154 T		04-02-97
EP 426857 A	15-05-91	CA 2026881 A		09-08-90
		WO 9009396 A		23-08-90
		US 5171837 A		15-12-92
US 5210075 A	11-05-93	NONE		